Diagnostic Performance of Three ELISAs for Detection of Antibodies against SARS-CoV-2 in Human Samples

Meira, Cássio Santana; Silva, Dahara; Santos, Ivanilson Pimenta; Barreto, Breno Cardim; Rocha, Vinícius Pinto Costa; Santos, Emanuelle de Souza; Reis, Bruna Padilha Zurita Claro dos; Evangelista, Afrânio Ferreira; Santos, Ricardo Ribeiro dos; Machado, Bruna Aparecida Souza; Ribeiro, Gabriel Sylvestre; Badaró, Roberto; Soares, Milena Botelho Pereira

doi:10.1155/2022/7754329

Cited by 3 publications

(3 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For IgG detection, sensitivity ranged from 76.31-94.7%, while IgM detection displayed more variability, ranging from 47.0-81.6%. However, all studies consistently achieved high specificities above 95% [24] , [25] , [26] , [27] , [28] , [29] . In one study, immunoassay accuracy using RBD for IgG detection reached 94.0%, surpassing our study's results [29] .…”

Section: Discussionmentioning

confidence: 86%

“…However, all studies consistently achieved high specificities above 95% [24] , [25] , [26] , [27] , [28] , [29] . In one study, immunoassay accuracy using RBD for IgG detection reached 94.0%, surpassing our study's results [29] . Commercial RBD-based tests, including VIDAS SARS-COV-2 RBD IgG (BioMérieux, Marcy-l'Etoile, France), Siemens SARS-CoV-2 RBD Total (COV2T) (Siemens, NY, USA), and the Access SARS-CoV-2 RBD IgG assay (Beckman-Coulter, CA, USA), reported specificities of 99.9%, 99.8%, and 99.8%, respectively.…”

Section: Discussionmentioning

confidence: 86%

See 1 more Smart Citation

Usefulness of receptor binding domain protein-based serodiagnosis of COVID-19

Vasconcelos,

Leony,

Camelier

et al. 2024

IJID Regions

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 86%

Section: Discussionmentioning

confidence: 86%

Usefulness of receptor binding domain protein-based serodiagnosis of COVID-19

Vasconcelos,

Leony,

Camelier

et al. 2024

IJID Regions

View full text Add to dashboard Cite

“…The ELISA for total IgG against the Spike protein followed the previously published protocol [ 25 ]. Serum samples from all participants were collected before vaccination, 30 days after receiving the first dose, and 30 days after the second dose.…”

Section: Methodsmentioning

confidence: 99%

High-Content Imaging-Based Assay for SARS-CoV-2-Neutralizing Antibodies

Rocha,

Machado,

Quadros

et al. 2024

Vaccines

Self Cite

View full text Add to dashboard Cite

The COVID-19 pandemic and the consequent emergence of new SARS-CoV-2 variants of concern necessitates the determination of populational serum potency against the virus. Here, we standardized and validated an imaging-based method to quantify neutralizing antibodies against lentiviral particles expressing the spike glycoprotein (pseudovirus). This method was found to efficiently quantify viral titers based on ZsGreen-positive cells and detect changes in human serum neutralization capacity induced by vaccination with up to two doses of CoronaVac, Comirnaty, or Covishield vaccines. The imaging-based protocol was also used to quantify serum potency against pseudoviruses expressing spikes from Delta, Omicron BA.1.1.529, and BA.4/5. Our results revealed increases in serum potency after one and two doses of the vaccines evaluated and demonstrated that Delta and Omicron variants escape from antibody neutralization. The method presented herein represents a valuable tool for the screening of antibodies and small molecules capable of blocking viral entry and could be used to evaluate humoral immunity developed by different populations and for vaccine development.

show abstract

The Evolution of Serological Assays during Two Years of the COVID-19 Pandemic: From an Easy-to-Use Screening Tool for Identifying Current Infections to Laboratory Algorithms for Discovering Immune Protection and Optimizing Vaccine Administration

Nicolai,

Tomassetti,

Pignalosa

et al. 2024

COVID

View full text Add to dashboard Cite

The emergence of COVID-19 has evolved into a global pandemic, causing an unprecedented public health crisis marked by unprecedented levels of morbidity never seen in the recent past. Considerable research efforts have been made in the scientific community to establish an optimal method to identify severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and to understand the induced immune response. This review examined the development of serological tests during the COVID-19 pandemic, considering the factors affecting sensitivity and specificity, which are key to promote an efficient vaccination strategy for public health. The market has witnessed the introduction of various serological tests for the detection of SARS-CoV-2, such as the chemiluminescence immunoassay (CLIA), which emerged as a powerful and rapid tool to monitor the antibody response before and after vaccination or infection. Therefore, developing serological tests by studying antibody trends and persistence is essential for creating long-term strategies. Our analysis underscores the multifaceted applications of serological tests in pandemic management with a focus on the critical insights they provide into antibody dynamics that help in managing the ongoing pandemic and shaping future public health initiatives, providing a basis for optimizing the future response to viral threats.

show abstract

Diagnostic Performance of Three ELISAs for Detection of Antibodies against SARS-CoV-2 in Human Samples

Cited by 3 publications

References 46 publications

Usefulness of receptor binding domain protein-based serodiagnosis of COVID-19

Usefulness of receptor binding domain protein-based serodiagnosis of COVID-19

High-Content Imaging-Based Assay for SARS-CoV-2-Neutralizing Antibodies

The Evolution of Serological Assays during Two Years of the COVID-19 Pandemic: From an Easy-to-Use Screening Tool for Identifying Current Infections to Laboratory Algorithms for Discovering Immune Protection and Optimizing Vaccine Administration

Contact Info

Product

Resources

About